+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline Review, H2 2020

  • ID: 5146867
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 119 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Biogen Inc
  • ChemoCentryx Inc
  • Humanigen Inc
  • Iltoo Pharma
  • Kyowa Kirin Co Ltd
  • Nanolek LLC
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Granulomatosis with Polyangiitis - Pipeline Review, H2 2020, provides an overview of the Granulomatosis with Polyangiitis (Immunology) pipeline landscape.

Wegener Polyangiitis is an uncommon disorder that causes inflammation of blood vessels. This inflammation restricts blood flow to various organs. Signs and symptoms include constantly runny nose, nose bleeds, ear infections, cough, chest pain, skin sores and fever. Predisposing factor includes age. Treatment includes immunosuppressive and corticosteroids.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Granulomatosis with Polyangiitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Granulomatosis with Polyangiitis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Granulomatosis with Polyangiitis (Immunology) pipeline guide also reviews the key players involved in therapeutic development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II and Preclinical stages are 2, 2, 3, 2 and 4 respectively.

Granulomatosis with Polyangiitis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Granulomatosis with Polyangiitis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Granulomatosis with Polyangiitis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Granulomatosis with Polyangiitis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Granulomatosis with Polyangiitis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Granulomatosis with Polyangiitis (Immunology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Granulomatosis with Polyangiitis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Granulomatosis with Polyangiitis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Biogen Inc
  • ChemoCentryx Inc
  • Humanigen Inc
  • Iltoo Pharma
  • Kyowa Kirin Co Ltd
  • Nanolek LLC
  • MORE
Introduction
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Overview
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Therapeutics Development
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Therapeutics Assessment

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Companies Involved in Therapeutics Development

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Drug Profiles

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Dormant Projects
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Discontinued Products
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Product Development Milestones
Appendix

List of Tables
  • Number of Products under Development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Biogen Inc, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Bristol-Myers Squibb Co, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by ChemoCentryx Inc, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by GlaxoSmithKline Plc, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Humanigen Inc, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by iBio Inc, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Iltoo Pharma, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by InflaRx NV, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Kyowa Kirin Co Ltd, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Mabion SA, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Nanolek LLC, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Pharmapraxis, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Dormant Projects, H2 2020
  • Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • Biogen Inc
  • Bristol-Myers Squibb Co
  • ChemoCentryx Inc
  • GlaxoSmithKline Plc
  • Humanigen Inc
  • iBio Inc
  • Iltoo Pharma
  • InflaRx NV
  • Kyowa Kirin Co Ltd
  • Mabion SA
  • Nanolek LLC
  • Nichi-Iko Pharmaceutical Co Ltd
  • Pharmapraxis
Note: Product cover images may vary from those shown
Adroll
adroll